Immunoconjugates targeting syndecan-1 expressing cells and use thereof

摘要

Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.

主权项

1. A method for treating a patient having CD138 expressing tumor cells comprising
administering to said patient at least one immunoconjugate in therapeutically effective amount, wherein said immunoconjugate comprises at least one effector molecule, wherein said effector molecule is a maytansinoid and has a molecular weight of less than 2 kDa and at least one targeting antibody selectively targeting cell-surface expressed CD138, wherein the targeting antibody binds to a linear epitope between residues 90-95 of the core protein on human CD138, and wherein said immunoconjugate delivers said effector molecule to said CD138 expressing tumor cells and said effector molecule is released.